Table 5 Vaccines entering Phase III/IV clinical trials (as of October 12, 2021)
From: Advances in the design and development of SARS-CoV-2 vaccines
Vaccine platform description | Type of candidate vaccine | Developers | Phase | References |
|---|---|---|---|---|
Inactivated virus | CoronaVac; inactivated SARS-CoV-2 vaccine (Vero cell) | Sinovac Research and Development Co., Ltd | Phase IV | |
Inactivated virus | Inactivated SARS-CoV-2 vaccine (Vero cell) | Sinopharm + China National Biotec Group Co + Wuhan Institute of Biological Products | Phase III | |
Inactivated virus | Inactivated SARS-CoV-2 vaccine (Vero cell), vaccine name BBIBP-CorV | Sinopharm + China National Biotec Group Co + Beijing Institute of Biological Products | Phase IV | [148] |
Viral vector (Non-replicating) | ChAdOx1-S - (AZD1222) Covishield Vaxzevria | AstraZeneca + University of Oxford | Phase IV | [149] |
Viral vector (Non-replicating) | Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) | CanSino Biological Inc./Beijing Institute of Biotechnology | Phase IV | [150] |
Viral vector (Non-replicating) | Gam-COVID-Vac Adeno-based (rAd26-S + rAd5-S) | Gamaleya Research Institute; Health Ministry of the Russian Federation | Phase III |  |
Viral vector (Non-replicating) | Ad26.COV2.S | Janssen Pharmaceutical Johnson & Johnson | Phase IV | [151] |
Protein subunit | SARS-CoV-2 rS/Matrix M1-Adjuvant (Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M) NVX-CoV2373 | Novavax | Phase III | [152] |
RNA based vaccine | mRNA-1273 | Moderna + National Institute of Allergy and Infectious Diseases (NIAID) | Phase IV | [153] |
RNA based vaccine | BNT162b2 (3 LNP-mRNAs), also known as "Comirnaty" | Pfizer/BioNTech + Fosun Pharma | Phase IV | [154] |
Protein subunit | Recombinant SARS-CoV-2 vaccine (CHO Cell) | Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences | Phase III |  |
RNA based vaccine | CVnCoV vaccine | CureVac AG | Phase III | [155] |
Inactivated virus | SARS-CoV-2 vaccine (Vero cell) | Institute of Medical Biology + Chinese Academy of Medical Sciences | Phase III | [156] |
Inactivated virus | QazCovid-in® - COVID-19 inactivated vaccine | Research Institute for Biological Safety Problems, Rep of Kazakhstan | Phase III | *1 |
DNA based vaccine | nCov vaccine | Zydus Cadila | Phase III | *2 |
Inactivated virus | Whole-virion inactivated SARS-CoV-2 vaccine (BBV152); Covaxin | Bharat Biotech International Limited | Phase III | Â |
Protein subunit | VAT00002: SARS-CoV-2 spike protein with adjuvant | Sanofi Pasteur + GSK | Phase III | [157] |
Inactivated virus | Inactivated SARS-CoV-2 vaccine (Vero cell) | Shenzhen Kangtai Biological Products Co., Ltd | Phase III | *3 |
Protein subunit | FINLAY-FR-2 anti-SARS-CoV-2 vaccine (RBD chemically conjugated to tetanus toxoid plus adjuvant) | Instituto Finlay de Vacunas | Phase III | *4 |
Protein subunit | EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Phase III | [158] |
Protein subunit | RBD (baculovirus production expressed in Sf9 cells) Recombinant SARS-CoV-2 vaccine (Sf9 Cell) | West China Hospital + Sichuan University | Phase III | *5 |
RNA based vaccine | SARS-CoV-2 mRNA vaccine (ARCoV) | Academy of Military Science (AMS), Walvax Biotechnology and Suzhou Abogen Biosciences | Phase III | [159] |
Protein subunit | CIGB-66 (RBD + aluminium hydroxide) | Center for Genetic Engineering and Biotechnology (CIGB) | Phase III | *6 |
Inactivated Virus | VLA2001 | Valneva, National Institute for Health Research, United Kingdom | Phase III | *7 |
Protein subunit | Recombinant Sars-CoV-2 Spike protein, Aluminum adjuvanted (Nanocovax) | Nanogen Pharmaceutical Biotechnology | Phase III | [160] |
Inactivated Virus | ERUCOV-VAC, inactivated virus | Erciyes University, Turkey | Phase III | *8 |
RNA based vaccine | mRNA-1273.351. A lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike protein of the SARS-CoV-2 B.1.351 variant | Moderna + National Institute of Allergy and Infectious Diseases (NIAID) | Phase IV | [161] |